Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

denileukin diftitox

Known as: Diphtheria toxin precursor, NAD(+--diphthamide ADP- ribosyltransferase), Interleukin-2 Fusion Protein 
A cytotoxic recombinant protein consisting of interleukin-2 (IL-2) protein sequences fused to diphtheria toxin. The IL-2 protein sequence moiety of… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
  • C. L. Ventola
  • P & T : a peer-reviewed journal for formulary…
  • 2017
  • Corpus ID: 5566005
Nanomedicine is a relatively new and rapidly evolving field combining nanotechnology with the biomedical and pharmaceutical… Expand
  • figure 1
  • figure 2
  • table 1
  • table 1
  • figure 3
Highly Cited
2010
Highly Cited
2010
PURPOSE This phase III, placebo-controlled, randomized trial was designed to investigate efficacy and safety of two doses of… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2009
Highly Cited
2009
Acute graft-versus-host disease (aGVHD) is the primary limitation of allogeneic hematopoietic cell transplantation… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Review
2009
Review
2009
Objective: To review FDA approved and other potential uses of Ontak, denileukin diftitox. Methods: Information was obtained via… Expand
Highly Cited
2007
Highly Cited
2007
CD4+CD25+Foxp3+ regulatory T (Treg) cells have been implicated in the lack of effective antitumor immunity. Denileukin diftitox… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Review
2006
Review
2006
  • F. Foss
  • Seminars in oncology
  • 2006
  • Corpus ID: 42249137
Denileukin diftitox (ONTAK; Seragen Inc, San Diego, CA) is a fusion protein designed to direct the cytocidal action of diphtheria… Expand
Highly Cited
2005
Highly Cited
2005
Elimination of regulatory T lymphocytes may provide a way to break self-tolerance and unleash the anti-tumor properties of… Expand
Highly Cited
2005
Highly Cited
2005
In this study, we investigated whether elimination of CD4+/CD25+ Tregs using the recombinant IL-2 diphtheria toxin conjugate DAB… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Highly Cited
2001
Highly Cited
2001
PURPOSE The objective of this phase III study was to determine the efficacy, safety, and pharmacokinetics of denileukin diftitox… Expand
Highly Cited
1987
Highly Cited
1987
We have genetically replaced the diphtheria toxin receptor binding domain with a synthetic gene encoding interleukin-2 (IL-2) and… Expand